Neither of us know about LFB having multiple CD 20 antibodies…
Vin, it sounds as though nothing I say will convince you that the CD20 drug LFB just moved into phase-1 is not the CD20 drug under development with GTC. However, let me make one more attempt by referring you to the timeline chart in #msg-33482901.
In this chart, you’ll see that GTC’s CD20 program is listed as being in preclinical development for the duration of 2009 (and possibly beyond). If this drug had really started phase-1 a full year ahead of schedule, don’t you think GTC would’ve thought this was a positive development worthy of trumpeting in a press release?